Boehringer Inhaler Demonstrates Positive Results in Phase IIIb/IV COPD Trial

September 13, 2016

Boehringer Ingelheim released results from the Phase IIIb/IV in chronic obstructive pulmonary disease (COPD) that showed the Stiolto Respimat inhaler, combined with exercise training, helped patients walk for longer periods of time compared to placebo.

The trial also showed improvements in shortness of breath associated with physical activity. The data were presented at the European Respiratory Society International Congress in London.

After eight weeks, patients with moderate-to-severe COPD who used Respimat (tiotropium bromide+olodaterol) combined with exercise training, saw exercise capacity increase by 45.8 percent compared to those that received placebo and had no exercise training.

View today's stories